Business
Cash-Strapped Biohaven Sells Its Lead Epilepsy Drug to SK for Up to $795M
After a string of research setbacks, Biohaven traded its most advanced medicine for upfront cash and future royalties — an unusual move to part with a key asset just before pivotal data.